Palm Beach Post: IgA Nephropathy Foundation Launches Kidney Month Campaign Elevating Patient Voices and New Education Resources
The Post-Crescent: IgA Nephropathy Foundation Launches Kidney Month Campaign Elevating Patient Voices and New Education Resources
Immunoglobulin A (IgA) nephropathy, also called Berger disease, occurs when IgA antibodies clump, damage kidney filters, and cause blood and protein in the urine. Liver disease is the most common ...
The New England Journal of Medicine: A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of ...
AstraZeneca’s Ultomiris met its first co-primary endpoint in a Phase III trial for IgA nephropathy, significantly reducing urine protein levels by week 34. The result supports the drug’s potential as ...
IgA Nephropathy (IgAN) is an autoimmune kidney disease. Without treatment, it can cause a variety of complications. Treatment focuses on disease management and slowing disease progression. Also known ...
Gaia Coppock, MD, affirms that patient involvement in IgA nephropathy care is more important than ever, especially given the increasing complexity of treatment options. Active participation helps ...
IgA nephropathy mainly affects the kidneys, while IgA vasculitis can also involve your skin, joints, and digestive system. IgA vasculitis often appears suddenly with rash and pain, but IgA nephropathy ...
Business Wire: Otsuka Showcases New Efficacy and Safety Data of VOYXACT® (sibeprenlimab-szsi) in Patients with IgA Nephropathy (IgAN) at the 2026 ISN World Congress of Nephrology ...